Company intelligence / Profile preview
Mid-Atlantic BioTherapeutics
Doylestown, Pennsylvania, United Statesmabt.us ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
MABT's lead asset, IMT504 immunotherapy for rabies, has received Orphan Drug Designation and is preparing to enter pivotal adaptive late-stage clinical trials. The company also collaborates with Accelero Biostructures to develop novel USP30 inhibitors using advanced AI-driven structural biology platforms targeting neurodegenerative diseases.
- Therapeutic areas
- NeurologyInfectious Diseases
- Modalities
- Immunotherapy (IMT504 platform)Small molecules (USP30 inhibitors)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Accelero Biostructures (for AI-driven drug discovery of USP30 inhibitors)SMITM Capital Markets Ltd. ($5 million capital commitment post-NASDAQ listing)Connectyx Technologies Holdings Group Inc.Curative Biotechnology Inc. licensed technology from MABT.
Beyond the preview
Go deeper on Mid-Atlantic BioTherapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mid-Atlantic BioTherapeutics.